InspireMD (NYSE:NSPR) Now Covered by StockNews.com

Analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a report released on Saturday. The brokerage set a “sell” rating on the stock.

Separately, Piper Sandler reissued an “overweight” rating and issued a $4.50 price objective on shares of InspireMD in a research note on Tuesday, September 17th.

InspireMD Stock Performance

Shares of NSPR opened at $2.47 on Friday. The firm has a market cap of $61.58 million, a PE ratio of -3.34 and a beta of 0.91. InspireMD has a 52-week low of $1.81 and a 52-week high of $3.67. The business’s 50 day moving average price is $2.65 and its two-hundred day moving average price is $2.56.

InspireMD (NYSE:NSPR) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). The company had revenue of $1.74 million during the quarter, compared to analyst estimates of $1.74 million. InspireMD had a negative return on equity of 62.02% and a negative net margin of 388.67%. During the same quarter in the previous year, the business posted ($0.24) earnings per share. Research analysts predict that InspireMD will post -0.82 EPS for the current fiscal year.

Hedge Funds Weigh In On InspireMD

An institutional investor recently raised its position in InspireMD stock. Rosalind Advisors Inc. raised its stake in shares of InspireMD, Inc. (NYSE:NSPR) by 266.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,513,641 shares of the company’s stock after acquiring an additional 1,827,579 shares during the period. InspireMD comprises approximately 4.6% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 8th largest holding. Rosalind Advisors Inc. owned 10.08% of InspireMD worth $6,272,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.